Step 1 of 2
Advances in Alzheimer’s disease (AD) research are reshaping the understanding and clinical application of disease-modifying therapies. Review these slides to examine the evidence supporting amyloid-targeting monoclonal antibodies, including effects on cognitive and functional decline, long-term treatment outcomes, amyloid-related imaging abnormalities (ARIA), and practical considerations for patient selection and monitoring. The presentation also explores emerging therapeutic approaches targeting tau pathology and neuroinflammation, advances in fluid biomarkers, and evolving strategies for earlier intervention, treatment optimization, and combination therapy.